原始出處紀錄
決策級主要結果 (Topline)
Xilio Therapeutics 預計XTX501第1期數據將於2027年下半年公布
Xilio Therapeutics 已提供其 XTX501 計畫初步 Phase 1 資料的預期時間表，該計畫為 PD-1 / masked IL-2 雙特異性療法。公司預計在 2027 年下半年公布此資料，條件是 FDA 核准 investigational new drug (IND) 申請，目標時間為 2026 年年中。
關鍵事實
- 申報時間
- 2026年3月9日 下午12:00
- 事件
- 主要結果 (Topline)
- 方向
- 正面
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 xlo-ex99_1.htm EX-99.1 Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ® This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio’s programs; the ultimate safety, efficacy, and potential benefits of any of Xilio’s current or future product candidates in any indication; any potential indications or commercial opportunities of our product candidates; the timing and receipt of future payments under Xilio’s collaboration or partnership agreements with AbbVie and Gilead; Xilio’s preliminary, unaudi